Dr. Katherine Moretz, M.D
NPI: 1619191103
Total Payments
$153,570
2024 Payments
$5,936
Companies
76
Transactions
1,150
Medicare Patients
1,511
Medicare Billing
$435,698
Payment Breakdown by Category
Other$92,853 (60.5%)
Food & Beverage$21,621 (14.1%)
Travel$17,496 (11.4%)
Research$14,506 (9.4%)
Consulting$7,018 (4.6%)
Education$75.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,853 | 55 | 60.5% |
| Food and Beverage | $21,621 | 1,020 | 14.1% |
| Travel and Lodging | $17,496 | 54 | 11.4% |
| Unspecified | $14,506 | 12 | 9.4% |
| Consulting Fee | $7,018 | 4 | 4.6% |
| Education | $75.09 | 5 | 0.0% |
Payments by Type
General
$139,063
1,138 transactions
Research
$14,506
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Greenwich Biosciences, Inc. | $70,074 | 113 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $38,026 | 100 | $0 (2024) |
| Neurelis, Inc. | $17,222 | 64 | $0 (2024) |
| PFIZER INC. | $8,190 | 9 | $0 (2024) |
| Eli Lilly and Company | $6,366 | 6 | $0 (2022) |
| UCB, Inc. | $1,464 | 77 | $0 (2024) |
| Biogen, Inc. | $1,159 | 75 | $0 (2024) |
| EMD Serono, Inc. | $1,054 | 145 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $977.47 | 82 | $0 (2022) |
| Lundbeck LLC | $620.47 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,936 | 118 | JAZZ PHARMACEUTICALS INC. ($3,803) |
| 2023 | $33,984 | 176 | Neurelis, Inc. ($12,821) |
| 2022 | $29,703 | 168 | JAZZ PHARMACEUTICALS INC. ($23,435) |
| 2021 | $27,377 | 147 | Greenwich Biosciences, Inc. ($20,617) |
| 2020 | $13,772 | 142 | Greenwich Biosciences, Inc. ($11,476) |
| 2019 | $39,905 | 209 | Greenwich Biosciences, Inc. ($37,981) |
| 2018 | $1,488 | 102 | Biogen, Inc. ($260.29) |
| 2017 | $1,405 | 88 | UCB, Inc. ($270.62) |
All Payment Transactions
1,150 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/18/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $31.42 | General |
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Neuropsychiatry | ||||||
| 12/04/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: EPILEPSY | ||||||
| 12/02/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: RETT SYNDROME | ||||||
| 11/25/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Neurology | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $11.91 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/20/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $34.16 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $30.13 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Neurology | ||||||
| 11/08/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 11/06/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Neurology | ||||||
| 11/05/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: Rare Disease | ||||||
| 11/05/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $9.45 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $19.54 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: Neurology | ||||||
| 10/31/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: Rare Disease | ||||||
| 10/28/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | AQUESTIVE THERAPEUTICS, INC. | LIBERVANT (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Central Nervous System | ||||||
| 10/24/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/22/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $8,140 | 6 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $5,936 | 4 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $430.04 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 286 | 14,139 | $828,085 | $186,351 |
| 2022 | 11 | 355 | 9,986 | $413,077 | $106,102 |
| 2021 | 11 | 503 | 9,689 | $450,621 | $111,771 |
| 2020 | 8 | 367 | 1,375 | $164,098 | $31,474 |
Total Patients
1,511
Total Services
35,189
Medicare Billing
$435,698
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 40 | 13,800 | $722,430 | $170,859 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 69 | $32,775 | $4,879 | 14.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 46 | 81 | $17,010 | $3,521 | 20.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 38 | $22,800 | $3,419 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 54 | $13,500 | $2,441 | 18.1% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 15 | 15 | $18,750 | $1,191 | 6.4% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 50 | 82 | $820.00 | $40.41 | 4.9% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2022 | 20 | 4,700 | $246,045 | $60,433 | 24.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 18 | 4,910 | $46,645 | $23,176 | 49.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 112 | $52,620 | $8,236 | 15.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 84 | 91 | $22,750 | $4,674 | 20.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 18 | 27 | $11,907 | $2,949 | 24.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 12 | 25 | $15,000 | $2,438 | 16.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 27 | 42 | $8,820 | $2,032 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 12 | $6,300 | $1,596 | 25.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 20 | 20 | $2,520 | $534.04 | 21.2% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2022 | 13 | 16 | $160.00 | $16.95 | 10.6% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 22 | 31 | $310.00 | $16.43 | 5.3% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2021 | 20 | 3,800 | $198,930 | $46,515 | 23.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 18 | 5,355 | $50,873 | $24,615 | 48.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 201 | 212 | $96,460 | $17,602 | 18.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 113 | 124 | $31,000 | $6,847 | 22.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 28 | $16,940 | $4,285 | 25.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 33 | 63 | $13,088 | $3,253 | 24.9% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 17 | 24 | $10,584 | $2,820 | 26.6% |
About Dr. Katherine Moretz, M.D
Dr. Katherine Moretz, M.D is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Savannah, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619191103.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katherine Moretz, M.D has received a total of $153,570 in payments from pharmaceutical and medical device companies, with $5,936 received in 2024. These payments were reported across 1,150 transactions from 76 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($92,853).
As a Medicare-enrolled provider, Moretz has provided services to 1,511 Medicare beneficiaries, totaling 35,189 services with total Medicare billing of $435,698. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Savannah, GA
- Active Since 04/13/2007
- Last Updated 06/04/2012
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1619191103
Products in Payments
- Epidiolex (Drug) $70,074
- EPIDIOLEX (Drug) $37,040
- VALTOCO (Drug) $17,222
- NURTEC ODT (Drug) $8,311
- ACTHAR (Biological) $1,079
- APTIOM (Drug) $996.50
- JZP-385 $808.00
- Briviact (Drug) $786.61
- TYSABRI (Biological) $756.53
- BOTOX (Biological) $562.87
- KESIMPTA (Drug) $503.47
- Fintepla (Drug) $412.01
- DYSPORT (Drug) $404.19
- Mavenclad (Drug) $384.00
- Fycompa (Drug) $361.10
- Mavenclad (Biological) $350.85
- VYEPTI (Biological) $290.18
- Hizentra (Biological) $282.30
- Vimpat (Drug) $265.49
- EMGALITY (Drug) $194.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Savannah
Dr. John Hemphill, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $2.3M
Neurology with Special Qualifications in Child Neurology $2.3M
Dr. Eric Pearlman, M.d., Ph.d, M.D., PH.D
Neurology with Special Qualifications in Child Neurology — Payments: $604.33
Neurology with Special Qualifications in Child Neurology $604.33